Towards stage specific treatments: Effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 57, Issue , 2015, Pages 69-75

  Rapado Castro, Marta ^a,b,c   Berk, Michael ^a,b,d   Venugopal, Kamalesh ^d   Bush, Ashley I ^b   Dodd, Seetal ^d   Dean, Olivia M ^b,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d DEAKIN UNIVERSITY   (Australia)

Author keywords

Glutathione; N acetyl cysteine; Neuroprogression; Oxidative stress; Schizophrenia; Staging

Indexed keywords

ACETYLCYSTEINE; CHLORPROMAZINE; CLOZAPINE; OLANZAPINE; PLACEBO; NEUROLEPTIC AGENT;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADD ON THERAPY; ADULT; ARTICLE; BARNES AKATHISIA SCALE; CLINICAL GLOBAL IMPRESSION SCALE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EARLY INTERVENTION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIMPSON-ANGUS SCALE; SOCIAL AND OCCUPATIONAL FUNCTIONING ASSESSMENT SCALE; TREATMENT DURATION; CLINICAL TRIAL; DRUG COMBINATION; MULTICENTER STUDY; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ACETYLCYSTEINE; ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84911092120     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2014.10.002     Document Type: Article

References (56)

1. Altamura A.C., Pozzoli S., Fiorentini A., Dell'osso B. Neurodevelopment and inflammatory patterns in schizophrenia in relation to pathophysiology. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:63-70.
2. Alvarez-Jimenez M., Gleeson J.F., Henry L.P., Harrigan S.M., Harris M.G., Amminger G.P., et al. Prediction of a single psychotic episode: a 7.5-year, prospective study in first-episode psychosis. Schizophr Res 2011, 125(2-3):236-246.
3. Anderson G., Berk M., Dodd S., Bechter K., Altamura A.C., Dell'osso B., et al. Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:1-4. (1878-4216 (Electronic)).
4. Anderson G., Maes M., Berk M. Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:101-114.
5. Arango C., Rapado-Castro M., Reig S., Castro-Fornieles J., Gonzalez-Pinto A., Otero S., et al. Progressive brain changes in children and adolescents with first-episode psychosis. Arch Gen Psychiatry 2012, 69(1):16-26.
6. Barnes T.R. A rating scale for drug-induced akathisia. Br J Psychiatry 1989, 154:672-676.
7. Berk M., Copolov D., Dean O., Lu K., Jeavons S., Schapkaitz I., et al. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008, 64(5):361-368.
8. Berk M., Ng F., Dean O., Dodd S., Bush A.I. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci 2008, 29(7):346-351.
9. Berk M., Hallam K., Malhi G.S., Henry L., Hasty M., Macneil C., et al. Evidence and implications for early intervention in bipolar disorder. J Ment Health 2010, 19(2):113-126.
10. Berk M., Brnarbic A., Dodd S., Kelin K., Tohen M., Malhi G., et al. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disord 2011, 13(1):87-98.
11. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011, 35(3):804-817.
12. Berk M., Munib A., Dean O., Malhi G.S., Kohlmann K., Schapkaitz I., et al. Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia. J Clin Psychiatry 2011, 72(7):909-913.
13. Berk M., Malhi G.S., Gray L.J., Dean O.M. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci 2013, 34(3):167-177.
14. Bitanihirwe B.K., Woo T.U. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev 2011, 35(3):878-893.
15. Cropley V., Wood S.J., Pantelis C. Brain structural, neurochemical and neuroinflammatory markers of psychosis onset and relapse: is there evidence for a psychosis relapse signature?. Int Clin Psychopharmacol 2013.
16. Cuesta M.J., Garcia de Jalon E., Campos M.S., Ibanez B., Sanchez-Torres A.M., Peralta V. Duration of untreated negative and positive symptoms of psychosis and cognitive impairment in first episode psychosis. Schizophr Res 2012, 141(2-3):222-227.
17. Dean O.M., van den Buuse M., Bush A.I., Copolov D.L., Ng F., Dodd S., et al. A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. Curr Med Chem 2009, 16(23):2965-2976.
18. Dean O.M., Bush A.I., Berk M. Translating the Rosetta Stone of N-acetyl cysteine. Biol Psychiatry 2012, 71(11):935-936.
19. Dodd S., Maes M., Anderson G., Dean O.M., Moylan S., Berk M. Putative neuroprotective agents in neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:135-145.
20. Emsley R., Rabinowitz J., Medori R., G., Early Psychosis Global Working Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res 2007, 89(1-3):129-139.
21. Emsley R., Chiliza B., Asmal L., Harvey B.H. The nature of relapse in schizophrenia. BMC Psychiatry 2013, 13:50.
22. Fava G.A., Kellner R. Staging: a neglected dimension in psychiatric classification. Acta Psychiatr Scand 1993, 87(4):225-230.
23. Fendri C., Mechri A., Khiari G., Othman A., Kerkeni A., Gaha L. Oxidative stress involvement in schizophrenia pathophysiology: a review. Encéphale 2006, 32(2 Pt 1):244-252.
24. Ferreira A.P., Pasin J.S., Saraiva A.L., Ratzlaff V., Rossato M.F., Andrighetto R., et al. N-acetylcysteine prevents baker's-yeast-induced inflammation and fever. Inflamm Res 2012, 61(2):103-112.
25. Fraguas D., Gonzalez-Pinto A., Mico J.A., Reig S., Parellada M., Martinez-Cengotitabengoa M., et al. Decreased glutathione levels predict loss of brain volume in children and adolescents with first-episode psychosis in a two-year longitudinal study. Schizophr Res 2012, 137(1-3):58-65.
26. Goldman H.H., Skodol A.E., Lave T.R. Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry 1992, 149(9):1148-1156.
27. Guy W. Clinical Global Impressions (CGI). Early Clinical Drug Evaluation Unit (ECDEU) assessment manual for psychopharmacology 1976, US Department of Health, Education and Welfare, Washington, DC. revised ed.
28. Guy W. ECDEU assessment manual for psychopharmacology, revised 1976, 76-338. Publication Adm. Washington DC, US Department of Health, Education, and Welfare.
29. Hall R.C. Global assessment of functioning. A modified scale. Psychosomatics 1995, 36(3):267-275.
30. Hanson D.R., Gottesman I.I. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med Genet 2005, 6:7.
31. Hill M., Crumlish N., Clarke M., Whitty P., Owens E., Renwick L., et al. Prospective relationship of duration of untreated psychosis to psychopathology and functional outcome over 12years. Schizophr Res 2012, 141(2-3):215-221.
32. Insel T.R. Rethinking schizophrenia. Nature 2010, 468(7321):187-193.
33. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13(2):261-276.
34. Lavoie S., Murray M.M., Deppen P., Knyazeva M.G., Berk M., Boulat O., et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008, 33:2187-2199.
35. Lin A., Reniers R.L., Wood S.J. Clinical staging in severe mental disorder: evidence from neurocognition and. Br J Psychiatry Suppl 2013, 54:11-17.
36. Malla A.K., Bodnar M., Joober R., Lepage M. Duration of untreated psychosis is associated with orbital-frontal grey matter volume reductions in first episode psychosis. Schizophr Res 2011, 125(1):13-20.
37. McGlashan T.H. Is active psychosis neurotoxic?. Schizophr Bull 2006, 32(4):609-613.
38. McGorry P.D., Hickie I.B., Yung A.R., Pantelis C., Jackson H.J. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry 2006, 40(8):616-622.
39. McGorry P.D., Nelson B., Goldstone S., Yung A.R. Clinical staging: a heuristic and practical strategy for new research and better health and social outcomes for psychotic and related mood disorders. Can J Psychiatry 2010, 55(8):486-497.
40. Melle I., Larsen T.K., Haahr U., Friis S., Johannesen J.O., Opjordsmoen S., et al. Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis. Arch Gen Psychiatry 2008, 65(6):634-640.
41. Mico J.A., Rojas-Corrales M.O., Gibert-Rahola J., Parellada M., Moreno D., Fraguas D., et al. Reduced antioxidant defense in early onset first-episode psychosis: a case-control study. BMC Psychiatry 2011, 11:26.
42. Ng F., Berk M., Dean O., Bush A.I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008, 11(6):851-876.
43. Pantelis C., Velakoulis D., McGorry P.D., Wood S.J., Suckling J., Phillips L.J., et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003, 361(9354):281-288.
44. Perkins D.O., Gu H., Boteva K., Lieberman J.A. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005, 162(10):1785-1804.
45. Saetre P., Emilsson L., Axelsson E., Kreuger J., Lindholm E., Jazin E. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 2007, 7:46.
46. Schimmelmann B.G., Huber C.G., Lambert M., Cotton S., McGorry P.D., Conus P. Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Res 2008, 42(12):982-990.
47. Shungu D.C. N-acetylcysteine for the treatment of glutathione deficiency and oxidative stress in schizophrenia. Biol Psychiatry 2012, 71(11):937-938.
48. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970, 212:11-19.
49. Sun D., Phillips L., Velakoulis D., Yung A., McGorry P.D., Wood S.J., et al. Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals. Schizophr Res 2009, 108(1-3):85-92.
50. Turner E.L., Dobson J.E., Pocock S.J. Categorisation of continuous risk factors in epidemiological publications: a survey of current practice. Epidemiol Perspect Innov 2010, 7:9.
51. van Haren N.E., Cahn W., Hulshoff Pol H.E., Kahn R.S. The course of brain abnormalities in schizophrenia: can we slow the progression?. J Psychopharmacol 2012, 26(5 Suppl):8-14.
52. Weinberger D.R. Biological phenotypes and genetic research on schizophrenia. World Psychiatr 2002, 1(1):2-6.
53. Wood S.J., Yucel M., Pantelis C., Berk M. Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Ann Acad Med Singapore 2009, 38(5):396-396.
54. Wood S.J., Yung A.R., McGorry P.D., Pantelis C. Neuroimaging and treatment evidence for clinical staging in psychotic disorders: from the at-risk staging mental state to chronic schizophrenia. Biol Psychiatry 2011, 70(7):619-625.
55. Wu J.Q., Kosten T.R., Zhang X.Y. Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013, 46:200-206. 10.1016/j.pnpbp.2013.02.015.
56. Yao J.K., Reddy R.D., van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001, 15(4):287-310.